Singh Primal P, Lemanu Daniel P, Soop Mattias, Bissett Ian P, Harrison Jeff, Hill Andrew G
Department of Surgery, South Auckland Clinical School, Faculty of Medical and Health Sciences, Auckland, New Zealand.
Department of Surgery, South Auckland Clinical School, Faculty of Medical and Health Sciences, Auckland, New Zealand.
J Am Coll Surg. 2016 Aug;223(2):308-320.e1. doi: 10.1016/j.jamcollsurg.2016.04.004. Epub 2016 Apr 13.
Statins have numerous potential benefits relevant to abdominal surgery, and their use has been associated with a reduction in the systemic inflammatory response syndrome, wound infection, and anastomotic leak after colorectal surgery. However, this clinical evidence is limited to retrospective studies. The aim of this study was to prospectively investigate whether perioperative statin therapy can decrease the incidence of complications after major colorectal surgery.
A prospective, double-blind, parallel-group, randomized controlled trial was conducted at 3 tertiary hospitals in New Zealand, between October 2011 and August 2013. Adult patients undergoing elective colorectal resection for any indication or reversal of Hartmann's procedure were randomized with a 1:1 patient allocation ratio to receive either 40 mg oral simvastatin or placebo once daily for 3 to 7 days preoperatively until 14 days postoperatively. The primary outcome was the overall incidence of complications for 30 days postoperatively. Secondary outcomes included the systemic and peritoneal cytokine response (interleukin [IL]-1α, IL-1β, IL-6, IL-8, IL-10, tumor necrosis factor [TNF]α) on postoperative day 1.
There were 132 patients included in the study (65 simvastatin, 67 placebo). There were no significant differences between the 2 groups at baseline with regard to patient, operation, and disease characteristics. There were no significant differences between the 2 groups in the incidence, grade, and type of postoperative complications (simvastatin: 44 [68%] vs placebo: 50 [75%], odds ratio 0.71 [95% CI 0.33 to 1.52], p = 0.444). Plasma concentrations of IL-6, IL-8, and TNFα, and peritoneal concentrations of IL-6 and IL-8, were significantly lower in the simvastatin group postoperatively.
Perioperative simvastatin therapy in major colorectal surgery attenuates the early proinflammatory response to surgery, but there were no differences in postoperative complications.
他汀类药物对腹部手术有诸多潜在益处,其使用与结直肠手术后全身炎症反应综合征、伤口感染及吻合口漏的减少有关。然而,该临床证据仅限于回顾性研究。本研究的目的是前瞻性调查围手术期他汀类药物治疗能否降低大型结直肠手术后并发症的发生率。
2011年10月至2013年8月期间,在新西兰的3家三级医院进行了一项前瞻性、双盲、平行组、随机对照试验。因任何适应症接受择期结直肠切除术或哈特曼手术逆转的成年患者,以1:1的患者分配比例随机分组,术前3至7天每天口服40mg辛伐他汀或安慰剂一次,直至术后14天。主要结局是术后30天并发症的总体发生率。次要结局包括术后第1天的全身和腹膜细胞因子反应(白细胞介素[IL]-1α、IL-1β、IL-6、IL-8、IL-10、肿瘤坏死因子[TNF]α)。
该研究纳入了132例患者(65例辛伐他汀组,67例安慰剂组)。两组在患者、手术和疾病特征的基线方面无显著差异。两组在术后并发症的发生率、分级和类型方面无显著差异(辛伐他汀组:44例[68%] vs安慰剂组:50例[75%],优势比0.71[95%CI 0.33至1.52],p = 0.444)。术后辛伐他汀组的血浆IL-6、IL-8和TNFα浓度以及腹膜IL-6和IL-8浓度显著较低。
大型结直肠手术围手术期辛伐他汀治疗可减轻手术早期的促炎反应,但术后并发症无差异。